Crossmark

Author Response: “iSTAND trial of IVIG in POTS: a step in the right direction, but more studies are needed”

Published Online: 2024-12-09

Published Print: 2025-04

Authors

Vernino, Steven https://orcid.org/0000-0001-7799-8495
Hopkins, Steve

Bryarly, Meredith
License Information

Text and Data Mining valid from 2024-12-09

Version of Record valid from 2024-12-09
More Information

Article History

Received: 22 November 2024

Accepted: 26 November 2024

First Online: 9 December 2024

Declarations

:

: SH: No disclosures. MB: Research support from Theravance. SV: Consultant for CSL Behring, Alterity, Argenx, and Theravance; and has received research support from NIH, Dysautonomia International, Sjogren’s Foundation, Grifols, and Takeda. SV serves on the scientific advisory board for Dysautonomia International and Mission MSA.

Document is current